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ess: j.c.davies@imperiaSummary Several studies have reported clinical improvements in cystic fibrosis
(CF) patients on macrolide antibiotics although the mechanism of action remains
unclear. We conducted an open-label study of azithromycin (500mg daily for 2
weeks) in 9 adult CF patients to explore 3 possible mechanisms: up-regulation of the
multi-drug resistance (MDR) or cystic fibrosis transmembrane regulator (CFTR)
proteins, correction of epithelial ion transport and reduced bacterial adherence.
End-points included nasal potential difference (PD) measurements, nasal epithelial
MDR and CFTR mRNA levels and Pseudomonas aeruginosa adherence to nasal
epithelium. Forced expiratory volume in the 1st second (FEV1) increased significantly
after 2 weeks of azithromycin (pre- 41.1 [5.0]%; post- 44.6 [5.8]%; Po0:05), although
improvements in forced vital capacity (FVC) did not reach significance (pre- 61.3
[4.0]%; post- 67.1 [5.4]%, NS). Before treatment all subjects had nasal PD
measurements characteristic of CF. Treatment led to no significant group differences
in any measures of either sodium absorption or chloride secretion. Neither CFTR nor
MDR mRNA levels had altered significantly and the adherence of P. aeruginosa did not
decrease. We conclude that these are unlikely to be significant contributing
mechanisms accounting for the consistent beneficial results observed in clinical
trials of macrolides in CF.
& 2005 Published by Elsevier Ltd.Published by Elsevier Ltd.
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Despite recent increases in survival, cystic fibrosis
(CF) is still associated with significant morbidity
and mortality, leading to the search for new
therapies. Following success with the macrolide
group of antibiotics in panbronchiolits,1 a disease
with many similarities to CF, we and others have
reported that this group of drugs leads to clinical
benefit in CF patients.2–4 Data from clinical and
laboratory studies suggest that these agents are not
acting as conventional antibiotics in vivo, which has
led to alternative hypotheses regarding their
mechanisms of action.
CF is caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR)
gene, which encodes an apically-situated epithelial
ion channel.5 Mutations lead to impaired secretion
of chloride and hyperabsorption of sodium across
the cell membrane.6 It is thought that these ion
transport defects lead to a dehydrated airway
surface liquid and subsequent impairment of
pulmonary mucociliary clearance.7 Chronic infec-
tion and an exaggerated inflammatory response
lead to irreversible airway damage and death from
respiratory failure in the majority of patients.8 One
proposed mechanism of action of macrolides is a
direct effect on either CFTR or related ion trans-
port proteins. CFTR belongs to the family of ATP
binding cassette (ABC) proteins along with the
multi drug resistance (MDR) gene product, P-
glycoprotein. The two share 80% sequence homol-
ogy and possess several common functions including
chloride transport.9 Reports of CF patients treated
with chemotherapy for co-existing malignancies,
have demonstrated pulmonary improvements
thought to be due to the upregulated MDR proteins
complementing deficient CFTR function.10 Macro-
lides have also been shown to upregulate the
expression of MDR in epithelial cells.11 In CF this
could either improve ion transport or affect other
functions of these proteins. Alternatively, normal-
isation of ion transport, either via improved
trafficking or function of the CFTR protein or
effects on other ion channels could lead to clinical
benefit. There have also been suggestions that
macrolides may exert an indirect anti-bacterial
effect, in the absence of effective bacterial killing.
Adherence of bacteria to cell surfaces is thought to
be an essential prerequisite to established infec-
tion and is increased to CF epithelial cells.12,13
Macrolides have been shown to reduce adherence
in both an animal model14 and a human study
on the buccal mucosa.15 Alternative hypotheses
for the benefits of the drugs include the inhibition
or breakdown of biofilm matrix,16,17 a directbactericidal effect on the slow-growing organisms
within a biofilm, or an anti-inflammatory effect.18
However, none of the recent clinical trials have
confirmed either significant antibacterial or anti-
inflammatory effects, despite clinical improve-
ment.2–4
An increased understanding of the mechanism(s)
of action of macrolides in CF could facilitate the
development of compounds with superior efficacy.
In this clinical study we assessed the effects of 2
weeks of azithromycin (AZM) on adult subjects with
CF, focussing on three possible mechanisms: CFTR
and MDR expression, epithelial ion transport and
Pseudomonas aeruginosa adherence.Materials and methods
Subjects
Adult CF subjects were recruited from the out-
patient clinic at the Royal Brompton Hospital. CF
had been diagnosed on standard criteria (positive
sweat test or mutation analysis in the context of a
suggestive clinical presentation). All subjects were
infected with P. aeruginosa with at least 3 positive
cultures of the organism from sputum over the
previous year. Due to the potential adverse effects
of azithromycin, exclusion criteria included: (a)
deafness (in either the subject or a first degree
relative at less than 40 years of age), (b) liver
disease (aspartate transaminase (AST) 43 times
the upper limit of normal, abnormal coagulation or
treatment with ursodeoxycholic acid), (c) any
macrolide therapy during the 2 months prior to
trial entry, (d) any positive sputum culture of
Burkholderia cepacia, (e) bilateral nasal polyps
(which can affect nasal PD measurements), (f)
upper respiratory tract infection within 3 weeks of
commencing the study and (g) breast feeding. The
study was approved by the Ethics Committee of the
Royal Brompton and Harefield NHS Trust and
informed consent was obtained from all patients.
Study protocol
The study protocol involved 6 visits over a 9-week
period as illustrated in Table 1. Following 3 pre-
treatment visits (V1–V3), patients received 500mg
oral AZM (Pfizer, UK) once daily for 14 days. They
were reviewed at the end of this 2-week period
(V4), 1 week later (V5, when tissue AZM levels
would still have been high), and finally, a further 3
weeks later (V6). PD measurements at V5 were
made in an attempt to confirm any drug effects
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Table 1 Flow chart of trial visits and investigations.
Week 1 2 3 4 5 6 7 8 9
Visit V1 V2 V3 V4 V5 V6
Spirometry X X X X X X
AZM Daily, 2 weeks
PD X X X X X X
Nasal brushing X X X
Patients attended on 6 occasions over a 9-week time period for the investigations indicated. Immediately after V3, patients
were commenced on AZM 500mg od for a total of 14 days.
Macrolides in cystic fibrosis 689observed at V4 and to limit the chances of missing a
delayed effect. All assays were performed at V6 in
order to demonstrate that any changes observed at
V4 or V5 had reversed, in support of a plausible
pharmacological effect of the drug. Lung function
was measured on a Vitalographs 2120 spirometer
and data are expressed as percent predicted for
age, sex and height.Nasal PD
These measurements were performed using a
conventional protocol as previously decribed.19 A
reference electrode was taped to the abraded skin
of the forearm. An initial skin PD of between 35
and 50mV was obtained in order to confirm the
integrity of the circuit. The exploring catheter was
then inserted below the inferior turbinate of one
nostril to the point of maximal (most negative) PD
and held by the patient for the duration of the
measurements. Infusions were perfused at a con-
stant rate of 4ml/min. The protocol included a
baseline measurement (Hepes) followed by re-
sponses to the sodium channel blocking agent,
amiloride (104 M for 3min), low chloride solution
and isoproterenol (105 M) for a total of 8min.
Unless otherwise stated, all chemicals and solutions
were obtained from Sigma Aldrich, UK, and were of
Analar grade or best available. Three recordings
were obtained prior to commencing AZM treat-
ment. Subsequent measurements were obtained at
the end of 14 days AZM, 1 week after stopping
treatment and again 4 weeks later. Traces were
assessed by an investigator blinded as to the timing
of the measurements.CFTR and MDR mRNA levels
Nasal epithelial cells were obtained by brushing
(3mm cytology brush, Diagmed, Thirsk, UK) the
inferior surface of the inferior turbinate of theopposite nostril to that used for PD measurements
at the time points indicated (Table 1). Previous
studies have shown that this method yields
approximately 4–10 105 cells.13 Cells were sus-
pended in phosphate-buffered saline (PBS) and
divided into two equal aliquots. One aliquot was
processed for reverse transcription-polymerase
chain reaction RT-PCR. Cells were suspended in
Dulbecco’s Modified Eagle Medium in RNase-free
microfuge tubes and split into 2 aliquots. One
sample was centrifuged for 10 s at 20,000g and the
pelleted cells were resuspended in 350 ml of RLT
buffer (Qiagen, Crawley, UK). The sample was
immediately placed on crushed dry ice before
storage at 80 1C. Total RNA was prepared using
RNeasy mini protocols (Qiagen). Levels of CFTR and
MDR were quantified in separate real-time quanti-
tative multiplex TaqMan RT-PCR reactions using ABI
PRISM 7700 Sequence Detection System and Se-
quence Detector v1.6.3 software (Applied Biosys-
tems, Warrington, Cheshire, UK). The
oligonucleotide primer and fluorogenic probe se-
quences were designed using Primer Express Soft-
ware version 1.5 (Applied Biosystems). CFTR
(ABCC7) mRNA was quantified using forward CFTR
primer (50-ggaaaaggccagcgttgtc-30), reverse CFTR
primer (50-ccaggcgctgtctgtatcct-30) and fluorogenic
CFTR probe (50-FAM-ccaaactttttttcagctggaccagac-
caa-TAMRA-30) encompassing bases 150–229 of the
CFTR cDNA sequence (NCBI:NM_000492) and span-
ning intron 1 of the CFTR gene. MDR (ABCB1) mRNA
was quantified using forward MDR primer (50-
tggttcaggtggctctg-30), reverse MDR primer (50-
ctgtagacaaacgatgagctatcaca-30) and fluorogenic
MDR probe (50-FAM-aggccagaaaaggtcggaccacca-
TAMRA-30) encompassing bases 2124–2195 of the
MDR cDNA sequence (NCBI:NM_000927) and span-
ning intron 14 of the MDR gene. Levels of 18 s
ribosomal RNA (rRNA) were simultaneously quanti-
fied when determining the levels of CFTR or MDR
mRNA using 18 s Ribosomal RNA Control Reagents
(Applied Biosystems, Warrington, UK). Total RNA
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transcribed with TaqMan RT reagents (Applied
Biosystems). The RT-reaction mix (5 ml) consisted
of 1 TaqMan RT buffer, 5.5mM MgCl2, 500 mM of
each dNTPs, 0.4 U/ml RNase inhibitor, 1.25 U/ml
Multiscribe Reverse Transcriptase, 0.4 mM CFTR or
MDR reverse primer, 0.4 mM reverse rRNA primer,
and approximately 5 ng total RNA. Reactions were
incubated at 48 1C for 30min followed by at 95 1C
for 5min. Subsequently, triplicate 25 ml PCR reac-
tions were performed for each sample. Each 25 ml
reaction consisted of 1 TaqMan Universal PCR
Mastermix (Applied Biosystems), 300 nM of the
appropriate forward and reverse primers, 100 nM
of the appropriate probe, 50 nM forward and
reverse rRNA primer, 50 nM rRNA probe and 5 ml
reverse-transcribed template. Reactions were in-
cubated at 50 1C for 2min, 95 1C for 10min followed
by 40 cycles of 95 1C for 15 s and 60 1C for 1min.
Controls included omission of reverse-transcribed
template and omission of reverse transcriptase and
RNase inhibitor. Relative levels of CFTR and MDR
mRNA in each sample were determined using the
DDCt method after adjustment for total RNA
content by normalisation to experimentally deter-
mined levels of rRNA.20 mRNA levels of all experi-
mental samples are expressed relative to the level
of expression observed at V3 in arbitrary units
termed Relative mRNA Expression (RME).Pseudomonas aeruginosa adherence
The other aliquot of nasal cells was used to assess P.
aeruginosa adherence as previously described.13
Cells were washed twice in PBS by centrifugation to
remove mucus and resuspended in 250 ml of PBS. A
laboratory reference strain of P. aeruginosa, Inter-
national Antigenic Typing Scheme (IATS) serotype
0:1 (NCTC 11440, ATCC 3348) was used. This strain
was chosen as it possesses pili, believed largely to
mediate adherence, and because in our previous
studies, adherence of this strain could be reduced
either by CFTR gene transfer13 or by blocking the
putative receptor, asialoGM1.21 The bacteria were
maintained at 4 1C on soft agar slants, plated onto
blood agar, and cultured overnight in Brain Heart
Infusion broth (Oxoid, Basingstoke, UK). Bacteria
were pelleted, resuspended in PBS and concentra-
tion adjusted by photospectrometry to approxi-
mately 5 109 CFU/ml (previously confirmed on
serial dilution and colony counting). Cells were
incubated with 50 ml of bacterial suspension at 37 1C
for 1 h, and then spun through 50% percoll
(Pharmacia, St. Albans, UK) to remove non-adher-
ent bacteria (30min; gav 20,000; 4 1C). The celllayer was removed, cytospun onto a thermanox
coverslip (Emitech, Ashford, Kent, UK) and fixed
overnight in 2.5% glutaraldehyde. Slides were
washed in sodium cacodolyte buffer (Merck, Poole,
UK), and dehydrated with serial concentrations of
ethanol followed by HMDS (TAAB, Aldermaston,
UK). Slides were mounted on aluminium stubs (Agar
Scientific, Stanstead, UK), sputtered with gold and
coded for the purposes of blinding. Samples were
viewed under the scanning electron microscope and
bacteria quantified on each single or small group of
cells within a field of view, when adhesion was
clearly seen to be directly to the cell surface rather
than related to mucus. Adherence was separately
quantified for the apical (ciliated) surface and the
basolateral surfaces of ciliated cells. Data are
presented as an adherence index based on the
numbers of bacteria binding to 10 cells.Statistical analysis
Changes pre (mean of V1–3 or V3 as stated) and
post AZM (V4, V5) were analysed using the Wilcoxon
signed rank sum test using SPSS v10. The null
hypothesis was rejected at Po0:05. For conveni-
ence, data are expressed as mean [SEM].Results
Nine patients (7 male) completed the six trial
visits. Mean age was 29.3 [2.5] years. Four patients
were homozygous for the DF508 mutation, 4 were
compound heterozygotes (DF508/ R347P, DF508/
G551D, DF508/, DF508/) and one patient had
no identifiable mutations. Lung function data for
each individual over the 3 pre-treatment assess-
ments (V1–V3) were pooled to give a single mean
baseline value for each subject. Mean values for
the whole group were FEV1 41.1 [5.0]% and FVC
61.3 [4.0]%. Following 2 weeks of treatment with
AZM, FEV1 had increased significantly (44.6 [5.8]%;
Po0:05) but change in FVC was not significant (67.1
[5.4]%) (Table 2).Nasal PD results
All patients had characteristic CF PD recordings at
the start of the study. The 3 measurements made at
weekly intervals before commencing treatment
were meaned to give a single pre-treatment value
(V1–V3; Table 1). Neither V4 nor V5 measurements
were significantly different from those at baseline
for any parameter of nasal PD (Fig. 1).
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Table 2 Clinical data of study subjects.
Patient (M/F) Age (years) FEV1/FVC(%) CFTR genotype
Pre-treatment (mean V1–V3) Post-treatment (V4)
1 (M) 42 26/63 26/63 DF508/ R347P
2 (M) 26 54.5/79 61/95 DF508/ DF508
3 (F) 25 61.5/66 66/72 DF508/G551D
4 (M) 19 27/48 29/50 DF508/
5 (M) 30 31/49 31/46 DF508/ DF508
6 (M) 30 38.5/72 46/83 DF508/ DF508
7 (F) 21 45/63 48/71 DF508/-
8 (M) 37 61/89 68/- DF508/ DF508
9 (M) 34 25/51 26/52 /
Macrolides in cystic fibrosis 691CFTR and MDR mRNA level
Brushings of nasal epithelial cells were taken for
RT-PCR analysis of CFTR and MDR mRNA levels at 3
time points: immediately before commencing AZM
(V3), after the 14-day course of treatment (V4) and
4 weeks after treatment had been completed (V6).
Total RNA preparation and CFTR and MDR mRNA
analysis was successful in 26 of the 27 available
samples. Both MDR and CFTR mRNA were detected
in all pre-treatment (V3) samples, but no significant
differences were observed after treatment, values
remaining essentially unchanged throughout the
study (Fig. 2). Three patients demonstrated greater
than 6-fold increases in MDR mRNA, of whom 2 also
showed a similar increase in CFTR mRNA. However,
these patients did not show significant changes in
either nasal PD or bacterial adherence.
Bacterial adherence
Samples were obtained at V3, V4 and V6. Samples
were of sufficient quality to be analysed in 7
patients at V3, 6 at V4 and 7 at V6. Pre-treatment,
the adherence index for the apical and basolateral
surfaces were similar to our previously published
values for CF subjects (8.37 [0.83] and 11.4 [1.40],
respectively). At the end of 2 weeks of AZM,
adherence to neither surfaces had changed (apical:
9.62 [1.72]) and baslolateral 9.93 [4.93]; Fig. 3).Discussion
Three placebo-controlled clinical trials have now
reported consistent clinical benefit from macro-
lides in patients with CF. In a double-blind placebo
controlled study in adult patients, Wolter et al.
reported significant effects on lung function,requirement for antibiotics and systemic inflamma-
tion as measured by C-reactive protein levels.3 We
conducted a placebo-controlled cross-over trial in
children and found a significant improvement FEV1,
but no effect on either bacterial density or sputum
inflammatory markers.2 Most recently, Saiman et
al. reported on a multi-centre study also demon-
strating significant lung function improvements and
fewer intravenous antibiotic courses in patients on
treatment.4 Long-term treatment with macrolides
has become part of routine management for certain
groups of patients in many CF centres. Despite this,
the mechanism(s) of action of these drugs in CF
remain unclear.
The aim of this study was to explore 3 possible
mechanisms: (a) upregulation of either CFTR or
MDR proteins; (b) improved ion transport in the
absence of protein upregulation, for example, by
enhanced CFTR trafficking or function; (c) reduced
adherence of P. aeruginosa. From this study, we
conclude that none of these mechanisms provides
an explanation for the consistent benefits observed
in several clinical trials.
The first hypothesis to be explored was that AZM
upregulated either CFTR or MDR expression. Lalle-
mand et al. reported a patient with CF who
demonstrated a dramatic improvement in lung
function after treatment for a fibrosarcoma.10 The
authors hypothesised that combination chemother-
apy led to upregulation of MDR protein, which
complemented the functions of CFTR. In support of
this, levels of MDR mRNA were increased in this
patient’s nasal epithelium, whereas they were
undetectable in another CF patient who had not
received chemotherapy. In view of the patient’s
persistently raised sweat electrolytes, the authors
concluded that this effect was not related to
normalisation of chloride ion transport, but sug-
gested that an alternative function of CFTR, such as
glutathione transport, had been complemented.
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Figure 1 Nasal PD (a) Baseline measurements, (b) responses to amiloride, (c) responses to low chloride solution and
isoproterenol. For each of the measurements, values for individuals obtained on visits 1–3 were meaned and are
represented as zero for ease of visualisation. All post-treatment values are presented as changes from baseline. Data
points represent group means and bars SEM. No significant changes were observed in any parameter after 2 weeks of
AZM treatment (V4) or 1 week later (V5).
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Figure 2 CFTR and MDR mRNA levels: The levels of CFTR (a) and MDR (b) mRNA were determined in nasal brushings
taken from each study subject on visits 3,4 and 6. Post-treatment data are presented as changes from baseline
(anchored at 1 RME). Data points represent group means and bars SEM. No differences were observed in either
parameter when comparing values pre (V3)-and post (V4)-AZM treatment.
Macrolides in cystic fibrosis 693Erythromycin, a member of the macrolide group of
antibiotics has also been reported to upregulate
expression of MDR protein in epithelial cells,11
leading to the suggestion that this could be the
mechanism of action of azithromycin in CF pa-
tients.22 We have previously designed protocols
capable of sensitive detection of even small
amounts of mRNA with real-time RT-PCR,23 and
have applied this TaqMan technology to measure
levels of CFTR and MDR mRNA in the current study.
For the group as a whole, there were no significant
changes in levels of either mRNA. However, 3 of the
9 patients demonstrated large (46-fold) increases
in MDR mRNA, and in 2 of these (DF508/DF508 and
DF508/G551D), similar increases were also ob-
served for CFTR mRNA. These subjects did not
demonstrate any significant changes in nasal PD,
making it unlikely that improved ion transport
resulted from this upregulation. Furthermore, as
only mRNA was measured, the effect of this change
on CFTR or MDR protein levels is unknown. It is
possible that other, unmeasured, functions of these
ABC proteins were complemented, but given the
lack of change in the group as a whole, we consider
that this mechanism is an unlikely explanation for
the consistent benefits in clinical trials.
The second hypothesis to be tested was that AZM
improved ion transport. Correction of abnormal ion
transport could result from altered expression of
relevant proteins as discussed above, or alterna-
tively, trafficking of mutant CFTR to the apical cell
surface, enhanced CFTR function, or indirect
effects on interactions with other proteins, such
as the epithelial sodium channel, ENaC. Pradal et
al. have reported in abstract form, that AZMtreatment led to normalisation of the nasal PD
response to zero chloride perfusion in 6 of 10 CF
patients receiving the drug for a month.24 In their
study, the underlying mechanism was not further
explored, although interestingly, subsequent perfu-
sion with isoproterenol did not result in further
chloride secretion, and baseline PD was not
altered. Baseline PD is largely a measure of sodium
absorption, and is increased in CF due to loss of the
inhibitory action of normal CFTR on ENaC. Thus, the
observation that chloride secretion was improved
in the absence of changes in sodium transport
might be explained by a drug effect on MDR rather
than CFTR. However, both proteins are regulated
by cAMP, so the lack of response to the cAMP
agonist, isoproterenol is more difficult to explain.
We performed repeated nasal PD measurements
using a conventional protocol19 to assess both
sodium transport (baseline and amiloride re-
sponses) and chloride secretion (response to low
chloride solution and isoproterenol). Overall, there
were no significant changes in any of these
parameters. Despite the lack of significance, it is
apparent from Fig. 1 that for each of the
parameters, the trend was in the direction of
normalisation, ie lower baseline and amiloride
responses and greater LCI responses. Post hoc
power calculations determined that for the changes
observed at V4 to have reached significance
(Po0:05 with 80% power) the number of subjects
would have to have been increased to either 44 (for
LCI) or 55 (baseline). Interestingly, the trend
towards normalisation appears to continue out to
V5. We cannot rule out the possibility therefore,
that had we included greater patient numbers or
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Figure 3 P. aeruginosa adherence: Bacteria were quantified separately on the apical, ciliated (a) surface and
basolateral (b) surfaces of cells obtained by nasal brushing. Symbols represent individual patients and are linked when
data from consecutive time points were available. Long bars represent group means. No reduction in adherence to
either surface was observed following AZM treatment (V4).
A.C. Equi et al.694continued treatment for longer, we might have
seen a significant effect on ion transport. However,
these relatively modest effects seem unlikely to
account for the much more dramatic effects on
lung function observed in clinical macrolide trials.
Finally, we attempted to address the possibility
that AZM was exerting a therapeutic effect by
reducing adherence of bacteria to the cell surface.
Macrolides do not appear to have a direct anti-
bacterial effect in CF; although these agents may
be bactericidal in vitro, particularly in synergy with
other drugs,25 clinical studies have reported no
change in sputum bacterial density. This led us to
consider other infection-related mechanisms. Many
groups have demonstrated increased binding of P.
aeruginosa to CF respiratory epithelial cells, most
likely related to an increased abundance ofreceptors.12,13,26 However, it is not at all clear
whether this increased adherence is relevant in
disease pathogenesis. Where tissue has been avail-
able, for example, at post-mortem or transplanta-
tion, bacteria are clearly seen to be in mucus in the
airway lumen, as opposed to directly adhering to
the epithelial surfaces.27 These tissues were ob-
tained in the late stages of disease, whereas
adherence to mucosal surfaces may be important
only in the early, acquisition stage of the process.
Alternatively, adherence of bacterial components
such as pili or flagellae may be more important than
that of the whole organism. Ligation of receptors
on the cell surface by such bacterial components
has been shown to lead to a brisk inflammatory
response, which is potentially detrimental to the
host.28 Baumann et al. demonstrated a significant
ARTICLE IN PRESS
Macrolides in cystic fibrosis 695reduction in P. aeruginosa adherence to buccal
epithelial cells from children treated with AZM for
3 months,15 leading us to believe that this could be
a potential mechanism for clinical benefit. Even if
adherence of whole bacteria were not a relevant
pathogenic mechanism in the lower airway, a
reduction in available binding sites could be
beneficial by reducing inflammation rather than
aiding clearance of organisms. We assessed P.
aeruginosa adherence to nasal epithelial cells
obtained by brushing. Using this technique we have
previously reported that the increased binding to
CF cells is directly related to mutant CFTR, in that
cationic liposome-mediated CFTR gene transfer ex
vivo significantly reduces adherence.13 In this
study, we were unable to demonstrate any effect
of 2 weeks’ AZM on adherence levels. One limita-
tion of interpretation is that analysable samples
were not available on all subjects at each of the 3
time points. Also, the assay is noisy, adherence
most likely being affected by other factors such as
upper respiratory tract infection or inflammation in
addition to the underlying CFTR defect. We
assessed a single set of experimental conditions,
based on previous studies and cannot rule out the
small possibility that we may have observed
changes under other conditions, for example,
longer incubation periods or different concentra-
tions. However, no trends towards a reduction were
apparent, and we therefore consider this an
unlikely explanation for the clinical benefits seen
in other studies.
We have explored 3 mechanisms which we
considered might account for the clinical efficacy
of macrolides in CF patients, and conclude that
these are unlikely to be significant contributory
factors. Limitations of this study include its size
and duration. We prospectively designed this study
on the basis of small numbers, based on the
increased power of paired statistical analysis and
the relatively invasive and burdensome assays
required of the patients. For both nasal PD and
bacterial adherence, data from our own studies29
and those of others7,30 have demonstrated signifi-
cant changes in response to treatments, even on
unpaired statistical analysis. We also deliberately
elected to make this study of short duration as,
based on available pharmacokinetic data,31,32 we
considered that changes in gene expression or
protein function would be likely to occur quickly,
whereas clinical changes used as measures of
success in previous trials may take longer. We
consider that the changes in spirometry observed
over this 2 week period led some support to this
design. However, this reasoning may be flawed, and
it certainly may not be the case for othermechanisms, which remain to be thoroughly ex-
plored. Alternative mechanisms of action of this
class of drugs include a wide variety of anti-
inflammatory effects including impairment of neu-
trophil chemotaxis,33 reduced levels of the pro-
inflammatory cytokine, IL-834 and inhibition of
superoxide generation,35 all potentially beneficial
to the CF airway. However, no studies in CF have
demonstrated changes in local inflammatory status;
although we examined sputum inflammatory mar-
kers in our longer-term paediatric study,2 we were
unable to provide any evidence in support of an
anti-inflammatory effect. Bacterial biofilms have
become a major area of interest lately, with recent
evidence that P. aeruginosa exists in the biofilm
state within the CF airway once chronic infection
has been established.36 In the early stages of
infection, bacteria exist in the free-floating,
planktonic state. Once a critical number of bacteria
has been reached, and if environmental conditions
are favourable, these bacteria settle down and
produce a matrix which surrounds them and
protects from the host immune response. Investi-
gators have demonstrated that macrolides are
effective in biofilm models,37,38 although the
underlying mechanisms, for example, breakdown
of matrix components, potentially facilitating
penetration of antimicrobial factors and inflamma-
tory cells, are undetermined. All of our patients
were infected with P. aeruginosa, but currently
assessment of biofilm in vivo is difficult and further
studies will be required to confirm whether this is
the mechanism leading to clinical benefit in
previous trials. Finally, these agents may be
reducing the viscosity of sputum,39,40 promoting
airway clearance and improving lung function in a
similar way to other mucolytic agents. This
possibility could also be addressed in future
studies.
In conclusion, in the context of CF, the beneficial
effects of macrolides do not appear to relate to the
ability of these agents to upregulate MDR or CFTR
proteins, correct ion transport, or to reduce P.
aeruginosa adherence. Future studies will explore
other mechanisms, a further understanding of
which may lead to the development of similar
classes of drugs with more potent effects.Acknowledgements
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